ABT vs EGBN · P/E 25, rev $44.33B vs rev $258.5M
Abbott Laboratories (ABT) versus Eagle Bancorp Inc (EGBN) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Eagle Bancorp Inc (EGBN) is a banks - regional company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported EGBN revenue for 2026-06-30 was $258.5M. Net income was $21.6M. Revenue was up 96.0% from 2026-03-31 to 2026-06-30. EGBN currently screens at market cap $788.3M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. EGBN currently screens at market cap $788.3M.
Not investment advice. Open the ABT and EGBN stock pages for the full models.
Not investment advice.